We similarly tested ES2 spheroids for viability in response to
combined SMIFH2 and cisplatin. Only at the highest cisplatin concentrations
alone was spheroid viability impacted (IC
¼ 12.5 mM)
(Fig. 2B). Interestingly, upon combined SMIFH2 with suboptimal
cisplatin concentrations (1e10
mM), there was a dramatic and
50
highly significant additive effect upon spheroid viability relative to
SMIFH2 or taxol treatments alone (Fig. 4C).
Finally, we tested cisplatin-resistant Skov3 spheroids with
combined SMIFH2/cisplatin treatment. Skov3 spheroids only saw
decreases in viability using 10
mM cisplatin (IC
¼ 15. 63 mM)
(Fig. 2D). We saw modest yet not statistically significant increases
in sensitivity to 10
mM cisplatin upon combined SMIFH2
treatment.